No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
AstraZeneca Pharma India Limited (AZPIL) functions as a biopharmaceutical company, involved in the manufacturing, distribution, and marketing of pharmaceutical products both within India and internationally. Its extensive product lineup includes medications for cardiovascular and diabetes conditions, marketed under brand names such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. The company also offers respiratory treatments like Symbicort and FASENRA, along with a comprehensive array of oncology drugs, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Beyond these, AZPIL provides therapies for renal, metabolic, and immunological disorders and delivers clinical trial services. Founded in 1979, this Bengaluru, India-based entity operates as a subsidiary of AstraZeneca Pharmaceuticals AB.
www.astrazeneca.inNo one on the platform currently holds ASTRAZEN.BO.
No tracked institution reports a position in ASTRAZEN.BO as of their last filing.
No one on the platform has traded ASTRAZEN.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 32.5% | 67.7% | 49.8% | — | — | — |
| Rev. Growth % | 32.8% | 23.0% | ||||
| Profit Margin % | 8.2% | 9.0% | 8.1% | |||
| Free Cash Flow Margin % | 0.1% | 4.3% | 5.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $8.4B | -16.7% | $33.34 | $33.34–$33.34 | — | 1 |
| 2028 | $8.4B | +0.0% | $33.34 | $33.34–$33.34 | — | 1 |
| 2029 | $9.1B | +8.1% | $32.31 | $32.31–$32.31 | — | 1 |
| 2030 | $10.1B | +11.0% | $36.51 | $36.51–$36.51 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-28 | $5.16 | $17.95 | +247.9% |
| 2026-02-09 | $8.29 | $13.04 | +57.3% |
| 2025-11-11 | $8.29 | $21.69 | +161.6% |
| 2025-08-14 | $8.29 | $22.33 | +169.4% |
| 2025-05-30 | $5.16 | $23.30 | +351.6% |
| 2025-02-11 | $8.29 | $12.34 | +48.9% |
| 2024-11-13 | $5.16 | $15.37 | +197.9% |
| 2024-08-08 | $8.29 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ASTRAZEN.BOAstraZeneca Pharma India Limited | $6693.35 | -1.23% | $167.4B | — |
| ERIS.BOEris Lifesciences Limited | $1311.00 | -3.25% | $181.7B | — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| JBCHEPHARM.BOJ. B. Chemicals & Pharmaceuticals Limited | $2412.25 | -3.70% | $387.3B | — |
| JBCHEPHARM.NSJ. B. Chemicals & Pharmaceuticals Limited |
| $-4.72 |
| -156.9% |
| $2416.10 |
| +0.30% |
| $387.9B |
| — |
| NEULANDLAB.BONeuland Laboratories Limited | $22522.85 | -3.87% | $289.5B | — |
| NEULANDLAB.NSNeuland Laboratories Limited | $22595.00 | -3.99% | $289.9B | — |
Source: Financial Modeling Prep · peers by sector/industry